Mirati Therapeutics, Inc. Profile Avatar - Palmy Investing

Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinic…
Biotechnology
US, San Diego [HQ]
US Spending For MRTX Over Time · Important Awards

Government Awards Analysis

Obligations Over-Time

Awards
Obligations

Mirati Therapeutics, Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$
IDVs
$
Direct Payments
$
Grants
$
Loans
$
Other Payments
$
vs.
Contracts
$
IDVs
$
Direct Payments
$
Grants
$
Loans
$
Other Payments
$
YoY Trends
  • No trends presentable, due to the lack of government contracts at all.

Spending By Type

Awards
Obligations
Contracts IDV Contracts Grants Loans Direct Other

Mirati Therapeutics, Inc. can't present spending by time.

Contract Analysis Updated: Recently

There are no contract award details available for Mirati Therapeutics, Inc.